Individualized Tailoring of Hypolipidemic Pharmacological Treatment
Keywords:dyslipidemia, hypercholesterolemia, lipid-lowering, treatment, statins, ezetimibe, fibrates, lipoproteins, coronary artery disease
The validation of the lipid hypothesis, which pertains to the relationship between dyslipidemia and atherogenesis, has established the central role of hypolipidemic treatment in the frontline of primary and secondary prevention of coronary artery disease. However, the complexity of the lipoprotein disorders, which are usually associated with more than one biochemical abnormalities, and the availability of several hypolipidemic agents in the existing therapeutic armamentarium with combined beneficial effects of variable intensity on several lipoproteins, have stressed the need for the development and implementation of easily applicable therapeutic algorithms which will enable the individualized tailoring of hypolipidemic management with maximal efficiency and safety. One such algorithm of individualized tailoring of hypolipidemic therapy is being proposed in this brief overview.
LicenseAuthors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).